More articles from Editorial
- The metabolic syndrome: A tug-of-war with no winner
Even before beta cells fail, the deadly quartet is quietly rehearsing.
- Making good decisions about diet: Weight loss is not weight maintenance
Lack of long-term data on very-low-carbohydrate diets makes their medically unsupervised use very troubling.
- Hormone replacement therapy: Applying the results of the Women’s Health Initiative
The ground rules have changed for prescribing hormone replacement therapy. Here are one expert’s recommendations.
- Hyperuricemia and gout: A reign of complacency
We physicians have become complacent about gouty arthritis, developing a false sense of confidence that we actually know how to manage it.
- Drug smuggling raises medical and legal issues
Smugglers are swallowing massive amounts of cocaine packaged in balloons or condoms. The treatment is controversial. And then there are ethical and legal questions.
- Hereditary hemochromatosis: Molecular genetic testing issues for the clinician
A DNA test exists, but who should be tested?
- Diagnosis of lupus: A glass half full
The tests will always be imperfect, but with better knowledge of how they perform, we can look at the clinical laboratory’s role in lupus diagnosis as a glass half full rather than half empty.
- Taking it to the bar: Medicolegal ramifications of perioperative steroid coverage
Will a jury side with an expert witness who cites “usual and customary” practice—or with one who cites published evidence?
- Bioterrorism: What practicing physicians can do
Given the specter of biological terrorism, the medical system has much to learn and much to do to prepare.
- Cox - 2 Inhibitors and Cardiovascular Risk
Even if we do not know with certainty whether COX-2 inhibitors increase the risk of cardiovascular events, we need to incorporate this concern into our practice.